TrialAnnals of the American Thoracic Society2026
Impact of 2 years of treatment with elexacaftor/tezacaftor/ivacaftor on longitudinal changes in structural lung disease in people with cystic fibrosis: results from the RECOVER trial.
Paul McNally et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.